Business Wire

Vodafone Spain and Twilio Partner to Offer Secure and Interactive RCS Messaging to Businesses in Spain

23.10.2025 11:00:00 EEST | Business Wire | Press release

Share

Twilio, the customer engagement platform that powers personalised, real-time experiences for today's leading brands, has announced an extended partnership with Vodafone Spain, one of the country's leading telecommunications operators. This will enable Spanish businesses to access Rich Communication Services (RCS) messaging, revolutionising the way they interact with their customers through rich, interactive and secure communications.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251023623745/en/

Vodafone Spain has relied on Twilio's global expertise to accelerate the adoption of this next-generation messaging solution, positioning it as the new standard for business communication in the Spanish market.

A much needed evolution for mobile communication

In a world where personalisation and trust are essential for brand to consumer relationships, RCS offers an experience that goes beyond the capabilities of traditional SMS. According to Twilio's State of Customer Engagement 2025 report, 81% of consumers prefer RCS over SMS, and 71% of businesses plan to adopt it in the next year.

With advanced features such as images, videos, product carousels, interactive buttons and verified senders, RCS transforms messages into more dynamic, human and relevant communications that generate greater impact and engagement. In addition, the ability of RCS to measure detailed metrics such as open rates, clicks and interactions allows businesses to optimise their campaigns in real time, maximising return on investment (ROI).

Trust and transparency have become central to customer expectations as spam and phishing attempts increase. RCS fully responds to these risks by enhancing the credibility and impact of brand communications.

Key benefits for businesses and users

  • Enhanced interactivity: RCS allows actionable buttons to be included directly in messages, facilitating actions such as purchases, reservations or surveys without having to leave the conversation.
  • Verified identity: Through branded messaging, a business can attach its name, brand logo, a tagline, and a verified badge to every text it sends, which means customers instantly recognise and can verify who’s reaching out.
  • Enriched experience: Multimedia content such as images, GIFs and videos enhances the user experience, making interactions more engaging and memorable.
  • Two-way communication: RCS encourages real-time conversations, allowing customers to resolve queries or make enquiries directly from the chat.
  • Advanced personalisation: Thanks to the integration of contextual data like purchase history, browsing history, and preference, companies can tailor messages to the specific preferences and needs of each customer.

A strategic collaboration to transform communications in Spain

Luis Suñer, Head of Wholesale MVNOs and Third Party Deals at Vodafone Spain, highlights: "We are delighted to partner with Twilio to bring RCS messaging to our business customers in Spain. This technology not only greatly enhances the quality of interactions between brands and consumers, but also reinforces trust and security while enhancing brand credibility. With RCS, businesses will be able to connect with their customers in a more relevant, dynamic and effective way."

Twilio’s EMEA VP of Marketing, Peter Bell, states: "This expanded partnership with Vodafone Spain is especially timely given the holiday season is upon us and is a make-or-break time for brands. With brands using RCS, especially for holiday messages, the engagement channel boasts 98% open rates and 45% response rates. Together with Vodafone, we are offering businesses a powerful tool to stand out in a competitive environment."

A promising future for business messaging

Thanks to this collaboration, Vodafone Spain customers will be able to harness the full potential of RCS to improve customer relationships, increase response rates and generate greater engagement. For users who do not yet have RCS-compatible devices, Twilio guarantees a smooth transition to the SMS format with the help of automatic failover, ensuring complete and continuous coverage.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251023623745/en/

Contacts

iperkins@twilio.com
00447931815123

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye